AMPD3

AMP deaminase 3 · Q01432 · AMPD3 on Sugi Atlas →

396 patent compounds predicted against AMPD3, 156 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15170127	0.66	19/20
SCHEMBL19462684	0.45	11/20
Pentostatin (SCHEMBL28078896)	0.54	5/20
Nitracrine (SCHEMBL28160229)	0.38	5/20
Pentostatin (SCHEMBL28265748)	0.46	4/20
Pentostatin (SCHEMBL28197957)	0.45	4/20
Pentostatin (SCHEMBL28886873)	0.61	3/20
SCHEMBL31415088	0.60	3/20
SCHEMBL20915109	0.57	3/20
Coformycin (SCHEMBL11184406)	1.00	2/20
Coformycin (SCHEMBL14031897)	1.00	2/20
SCHEMBL29823077	0.82	2/20
SCHEMBL29952186	0.69	2/20
Pentostatin (SCHEMBL2818)	0.67	2/20
Pentostatin (SCHEMBL1649740)	0.67	2/20
Pentostatin (SCHEMBL2045053)	0.67	2/20
Pentostatin (SCHEMBL5549091)	0.67	2/20
Pentostatin (SCHEMBL14031902)	0.67	2/20
SCHEMBL29885458	0.63	2/20
SCHEMBL29519718	0.59	2/20

Clinical trials — most relevant to AMPD3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Vitamin D Status in Patients With Severe Sepsis	PHASE3	WITHDRAWN
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)	PHASE2/PHASE3	COMPLETED
Fever and Neutropenia in Pediatric Oncology Patients	PHASE3	WITHDRAWN
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer	PHASE1	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis	nan	COMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Epigenetics, DNA Methylation Patterns and Periodontal Disease	nan	COMPLETED
Study of Selected X-Linked Disorders: Aicardi Syndrome	nan	RECRUITING
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Predisposition Genes in Monogenic Diabetes (DIAMONO)	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Genetics of Middle Ear Disease	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a AMPD3 binder may also engage these)

Protein	Name	Similarity
O08739	—	1.000	O08739 →
O09178	—	1.000	O09178 →
P10759	—	1.000	P10759 →
AMPD1	AMP deaminase 1	1.000	landscape →
AMPD2	AMP deaminase 2	0.998	landscape →
Q3V1D3	—	0.998	Q3V1D3 →
Q9DBT5	—	0.994	Q9DBT5 →
Q02356	—	0.994	Q02356 →
Q54DD0	—	0.993	Q54DD0 →
P50998	—	0.993	P50998 →
Q84NP7	—	0.992	Q84NP7 →
O80452	—	0.992	O80452 →
F4J8C6	—	0.991	F4J8C6 →
Q5XHF8	—	0.990	Q5XHF8 →
Q84WW3	—	0.990	Q84WW3 →
P15274	—	0.989	P15274 →
Q8MJ26	—	0.989	Q8MJ26 →
Q6ZQB6	—	0.989	Q6ZQB6 →
Q9VR59	—	0.989	Q9VR59 →
A7Z050	—	0.989	A7Z050 →
Q8VCB3	—	0.989	Q8VCB3 →
A2RRU1	—	0.989	A2RRU1 →
PPIP5K2	Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2	0.988	landscape →
P00365	—	0.988	P00365 →
O93869	—	0.988	O93869 →
Q9Z1E4	—	0.988	Q9Z1E4 →
Q6PFW1	—	0.988	Q6PFW1 →
P09810	—	0.987	P09810 →
Q9HBG4	—	0.987	Q9HBG4 →
GYS2	Glycogen [starch] synthase, liver	0.987	landscape →